Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.
Company Details
- Employees
- 56
- Founded
- -
- Address
- 2 Royal College Street, The London Bioscience Innovation Centre,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.purespringtx.com
- Keywords
- biotechnology, gene therapy, kidney diseases.
- HQ
- London
Purespring Therapeutics Questions
Purespring Therapeutics's website is http://www.purespringtx.com
Purespring Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/purespring-therapeutics
Purespring Therapeutics has
56 employees.
View email and phone details for 56
employees at Purespring Therapeutics.
Purespring Therapeutics's industry is
Biotechnology Research
Purespring Therapeutics's top competitors are
Upstream Bio,
Immatics,
Quell Therapeutics,
Resolution Therapeutics,
Aviadobio,
Scholar Rock,
Forcefield Therapeutics,
Judo Bio,
Syncona Limited,
City Therapeutics.
Purespring Therapeutics's categories are Biotechnology Research
Purespring Therapeutics's founding year is 2020
